United States: THC, CBD, And The FDA: What To Expect At The Federal And State Level

With CBD (cannabidiol) becoming mainstream and federal cannabis legalization on the horizon, many are asking how the U.S. Food and Drug Administration will regulate cannabis-based products going forward. The 2018 Farm Bill, which was signed in to law in December 2018, exempts hemp and hemp-derived products, including hemp-derived CBD, from the Controlled Substances Act (CSA). Prior to passage of the Farm Bill, there was widespread confusion about the extent of the "legality" of hemp-derived CBD, with many commentators and even some legal experts conflating legality under the CSA with legality under the Food, Drug, and Cosmetics Act (FDCA) and state food and drug laws. This confusion prompted FDA Commissioner Scott Gottlieb, M.D., to issue a public statement clarifying Congress had explicitly preserved the FDA's authority to regulate products containing cannabis or cannabis-derived compounds under the FDCA, regardless whether they are derived from cannabis or hemp.

A product containing cannabis or a cannabinoid potentially may be considered a drug, food, food additive, dietary supplement, or cosmetic, depending upon how the product is marketed and sold. How aggressively these products are policed by the FDA and state agencies depends on the nature of the product and how it is defined under the FDCA and state law.

Cannabis as a 'drug'

Under the FDCA's drug exclusion rule, once a substance is an active ingredient of an approved drug product or an active ingredient of a product in clinical trials that have been made public, a food or supplement containing that substance cannot be shipped in interstate commerce. Because the FDA previously authorized investigation of CBD and THC as new drugs—for which substantial clinical research already had been conducted and made public—CBD is considered a drug. The FDA has cited Epidiolex, Sativex, and Marinol as examples of clinical investigations regarding CBD and THC that have been made public. Epidiolex was approved by the FDA in June 2018 for treatment of childhood seizures associated with two rare forms of epilepsy. The FDA has therefore concluded that CBD products are in fact drugs and require FDA approval under the FDCA. The new drug approval process is exorbitantly expensive. In 2016, the Journal of Health Economics estimated the average cost per approved drug at well over $1 billion.

The FDA prohibits THC use for any reason due to its status as a Schedule I drug under the CSA. When THC is eventually removed from Schedule I, it very likely will be assigned to another schedule within the CSA and regulated as a drug pursuant to that schedule.

Cannabis as 'food'

Under the FDCA, food generally is defined as any item consumed primarily for taste, aroma, or nutritive value. It is doubtful cannabis or a cannabis-extract product would satisfy this test. In any event, the FDA has concluded THC and CBD must be excluded from foods due to the drug exclusion rule discussed above.

Cannabis as a 'food additive'

Every ingredient in a food sold in interstate commerce is a food additive and subject to FDA pre-approval requirements, unless an exception applies. Prior to adding a new food additive to a conventional food, one must obtain approval of a food additive petition, which can take years to complete. The primary exception is for a substance that is "generally recognized as safe," also known as "GRAS." A substance is GRAS if it is shown to be safe using "scientific procedures" or if it was used in food before January 1, 1958, and shown to be safe through "experience based on common use in food." Although GRAS determination has been made in the case of hulled hemp seeds, hemp seed protein, and hemp seed oil—which do not contain CDB—the FDA concludes further research is needed for CBD and presumably other cannabinoids as well. Future GRAS applications certainly will be made for CBD, but this must be done in accordance with the scientific process and will take time.

Cannabis as a 'dietary supplement'

The FDA has concluded THC and CBD products are not dietary supplements under the FDCA or the Dietary Supplement Health and Education Act (DSHEA) due to the drug exclusion discussed above. There is an exception if the substance was marketed as a dietary supplement before the drug was approved or the trials started. The FDA has concluded, however, that "this is not the case for THC or CBD" based on available evidence. Another exception involves the substance being marketed as a dietary supplement before October 15, 1994. Again, there is no substantial evidence of this type of marketing activity for any cannabinoid prior to that time. If no exception applies, it is necessary to submit a premarket notification to the FDA with results of premarket safety testing for the proposed dietary supplement.

One potentially could market a dietary supplement containing a cannabis-based new dietary ingredient if there was a "history of use or other evidence of safety" establishing that when used according to the direction in its labeling, the ingredient will "reasonably be expected to be safe." One first must submit a new dietary ingredient notification (NDI notification) at least seventy-five days before introducing the supplement to market. The FDA may send a "no objection" letter, but in the absence of a response from the FDA, one may legally market the dietary supplement after seventy-five days has expired. There is substantial risk of attempting to market any dietary supplement through this route without reliable scientific evidence of safety.

Cannabis as a 'cosmetic'

Cosmetics are less heavily regulated by the FDA than food and drugs, and the agency has not yet taken a public position on the use of CBD or other cannabinoids in cosmetic products. A company that wishes to market CBD in cosmetics should proceed with caution and recognize agency policy may change with little or no notice.

Smoking and vaping cannabis

Currently, cannabis flower that is smoked and cannabis oil that is vaped pursuant to intrastate adult-use cannabis markets falls outside FDA's jurisdiction. Even future interstate sale and use of these products likely will not be regulated by the FDA, because they lie outside scope of the agency's statutory mandate. Cannabis flower and oil that is ingested though smoking or vaping does not qualify as a food, supplement, or other substance over which FDA has regulatory authority. So long as no health or disease claims are made, these products also do not qualify as a drug under the FDCA.

FDA and state enforcement

Between 2015 and July 2018, the FDA sent several warning letters to companies that sold CBD-infused oils and food products in interstate commerce with associated health claims, but it took no other visible enforcement action against those companies. Since passage of the Farm Bill, however, there have been numerous reports of stepped-up enforcement action in several states by the FDA and state authorities. There are reports of unannounced inspections and CBD product embargos ordered by authorities in California, New York, and several other states. FDA personnel reportedly have participated in some of these inspections, with state personnel as the apparent lead agency. Several states and cities, including California, Maine, North Carolina, Ohio, and New York City, have banned CBD-infused food products under state and local laws. As cannabis-based products continue to enter interstate commerce, one should expect to see an increasingly robust response from both the FDA and state authorities.

The FDA has taken no action against cannabis edibles sold in states that have legalized adult-use or medical marijuana. This likely is because those products are not sold in interstate commerce and because those sales violate the CSA, such that they already are considered illegal under federal law.

On February 11, 2019, the FDA announced a broad new initiative to modernize dietary supplement regulation and oversight for the purpose of ensuring FDA achieves the right balance between preserving access to lawful supplements while protecting the public from unsafe or unlawful products. The impact of this new initiative on the legal pathway for CBD remains unclear at this time.

What comes next

Regarding a possible easing of restrictions on CBD and other cannabinoids, the FDA's public statement unfortunately contains only a vague assurance that the FDA will "make the pathways for the lawful marketing of these products more efficient." What this means is unclear. Although the statement references FDA's authority to "issue a regulation allowing the use of a pharmaceutical ingredient in a food or dietary supplement," it makes clear FDA will do so only if all other requirements in the FDCA are met, including those required for food additives or new dietary ingredients. These are not insignificant hurdles, as discussed above. The process can take years and often is exorbitantly expensive. In the meantime, the FDA remains under pressure due to intense public interest in these products.

This uncertainty has prompted multiple letters from Congress to FDA Commissioner Gottlieb. Oregon's two senators recently requested Gottlieb update "outdated regulations" prohibiting the sale across state lines of food products containing CBD. On February 15, 2019, a bipartisan group of members of Congress also sent a letter to Gottlieb calling on FDA to "swiftly provide guidance on lawful pathways for food products with CBD." The letter references significant confusion surrounding CBD and points out "numerous states are pursuing legislative efforts that would allow for the intrastate commerce of food products with CBD, potentially leading to a patchwork of state regulations."

Following receipt of the letter, Gottlieb testified before the House Appropriations Committee on February 27, 2019. In his testimony, he detailed the start of new regulatory plans for CBD. Initially, the FDA will hold a public meeting in April to hear from industry stakeholders about effective hemp-derived CBD regulations. Gottlieb also mentioned the FDA is forming a work group with "some senior officials in the agency" to study regulatory options for CBD. He noted that creating a regulatory framework for CBD "is not a straightforward issue" because CBD is a compound in an existing FDA-approved medication; therefor, under the FDCA, it cannot be added to products intended for human consumption. Nevertheless, hinting at a possible regulatory framework, Gottlieb said "CBD could potentially exist in a high-concentration, pure formulation as a pharmaceutical product" while also existing at lower concentrations that could be sold as foods and dietary supplements.

With respect to timing, Gottlieb acknowledged the possibility that promulgating CBD regulations could take longer than expected and testified he will seek congressional guidance to "have a discussion about whether or not there are other frameworks that could help address this" if the FDA determines the pathway to CBD regulations could be a multi-year process.

The expectation that the FDA will liberalize its position on CBD comes at a time when the agency is preparing to take a more aggressive stance on regulating the dietary supplement industry. Consistent with Gottlieb's recent congressional testimony, one should expect the FDA to maintain a fairly consistent position that CBD and other cannabinoids must follow the scientific process like any other chemical component, which will take many months at the minimum. Until then, vigilance is required.

Previously published in the April 18, 2019, edition of mg Magazine.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions